Every day, fake medicines and medical products are sold at street corners, in open air markets or on unregulated websites in several countries in the African Region. These poor quality, unsafe medicines and pharmaceutical products promote drug resistance and lead to loss of confidence in health prof...essionals, manufacturers and distributors and in health systems. In an effort to protect people’s health, the WHO Regional Director for Africa, Dr Matshidiso Moeti, has proposed a strategy aimed at strengthening National Medicine Regulatory Authorities (NMRAs) in order to ensure that only safe, good quality and effective medical products are available.
more
A workshop of “first mover” countries to exchange experience and identify wider policy implications for the WHO European Region
The World Health Organization (WHO) European Region continues to be severely affected by diet-related noncommunicable diseases (NCDs), obesity and, in some countries, ...micronutrient deficiencies.
In order to drive further progress on improving dietary intake and food product improvement, the WHO Regional Office for Europe, Public Health England and the Royal Institute of International Affairs (Chatham House) co-convened a workshop of “first mover” countries in March 2019.
more
Public Report
PQMC 0001-001-04 WHO PQMC Public Report November/2016, version 8.0
This report, published in conjunction with a summary overview of results of rounds 1–8, is the eighth and final report in a series of laboratory-based evaluations of rapid diagnostic tests (RDTs) for malaria. It provides a comparative measure of their performance in a standardized way to distingu...ish between well and poorly performing tests.
These results constitute the laboratory evaluation component of the WHO prequalification process for malaria RDTs and inform the current WHO procurement recommendations. In round 8, 35 RDTs from 17 manufacturers were assessed. For the first time the evaluation included an assessment of product performance against a panel of P. falciparum parasites with pfhrp2/3 gene deletions and therefore not expressing HRP2.
more
PQDx 0197-045-00 WHO
PQDx PR
March /2016, version 2.0
PQDx 0141-051-00 WHO
PQDx Public Report
April/2017, version 5.0
PQDx 0159-055-00
WHO PQ Public Report
February/2017, version 5.0
Public Report
PQMC 0003-003-00 WHO PQMC PR June/2015, version 2.0
PQDx 0053-006-00 WHO
PQ Public Report
June/2016, version 2.0
PQDx 0033-013-00 WHO
PQ Public Report
July/2016, version 5.0
PQDx 0005-005-00
WHO PQDx PR
May/2016, version 3.0
Rwanda Guidelines for variation to registered pharmaceutical products.
This guideline is intended to provide requirements to applicants wishing to submit
applications for registration of medicines in Botswana.
PQDx 0214-064-00
WHO PQDx PR
April/2016, version 3.0
PQDx 0198-071-00
WHO PQDx PR
April/2016, version 2.0
PQDx 0027-012-00 WHO
PQDx Public Report
May/2017, version 4.0